Anthony Quinn
Director/Board Member chez GENERATION BIO CO.
Fortune : 656 621 $ au 31/03/2024
Profil
Anthony G.
Quinn is an Independent Director at Kaleido Biosciences, Inc. and Generation Bio Co. He was the President, Chief Executive Officer & Director at Spyre Therapeutics, Inc. from 2018 to 2022.
He was also the Chief Medical Officer & Executive Vice President at Synageva BioPharma Corp.
from 2014 to 2015.
Prior to that, he was the Head-Clinical Research & Exploratory Development at Roche Palo Alto LLC from 2005 to 2009.
He was a Director-Experimental Medicine at AstraZeneca PLC and a Principal at Charnwood Group.
He was also a Professor at the London School of Hygiene & Tropical Medicine and St Bartholomew's Hospital Medical College.
He received his doctorate degree from Newcastle University in 1994 and his undergraduate and graduate degrees from the University of Dundee in 1982 and 1985, respectively.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GENERATION BIO CO.
0,24% | 01/12/2023 | 161 332 ( 0,24% ) | 656 621 $ | 31/03/2024 |
Postes actifs de Anthony Quinn
| Sociétés | Poste | Début |
|---|---|---|
| GENERATION BIO CO. | Director/Board Member | 01/12/2017 |
| KALEIDO BIOSCIENCES, INC. | Director/Board Member | 01/02/2016 |
Anciens postes connus de Anthony Quinn
| Sociétés | Poste | Fin |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Chief Executive Officer | 24/08/2022 |
| SYNAGEVA BIOPHARMA CORP | Chief Tech/Sci/R&D Officer | 01/06/2015 |
Roche Palo Alto LLC
 Roche Palo Alto LLC Pharmaceuticals: MajorHealth Technology Roche Palo Alto LLC discovers and develops medicines. Its medicines are used for the treatment of central nervous system, inflammation, metabolism, oncology, and virology diseases. The company was founded in 1961 and is headquartered in Palo Alto, CA. | Corporate Officer/Principal | 01/08/2009 |
| London School of Hygiene & Tropical Medicine | Corporate Officer/Principal | - |
| St Bartholomew's Hospital Medical College | Corporate Officer/Principal | - |
Formation de Anthony Quinn
| Newcastle University | Doctorate Degree |
| University Of Dundee | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| SPYRE THERAPEUTICS, INC. | Health Technology |
| KALEIDO BIOSCIENCES, INC. | Health Technology |
| GENERATION BIO CO. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Roche Palo Alto LLC
Roche Palo Alto LLC Pharmaceuticals: MajorHealth Technology Roche Palo Alto LLC discovers and develops medicines. Its medicines are used for the treatment of central nervous system, inflammation, metabolism, oncology, and virology diseases. The company was founded in 1961 and is headquartered in Palo Alto, CA. | Health Technology |
Charnwood Group
 Charnwood Group Containers/PackagingProcess Industries Charnwood Group is a British company that manufactures elastic products. The private company is based in Leicester, UK and has subsidiaries in the United Kingdom. | Process Industries |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
